Lymphoma Clinical Trials in Arizona

Showing 521-540 of 541 trials

Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

NCT00955786

This phase 1 study of CX-3543 is designed to test the safety, tolerability and highest safe dose level of this drug in patients with advanced solid tumor cancers.

Advanced Solid TumorsLymphoma

Cylene Pharmaceuticals48 participantsStarted Jul 2005

Scottsdale, Arizona, United States • San Antonio, Texas, United States

COMPLETEDPhase 242 miles

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

NCT00061672

The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.

Lymphoma, Non-HodgkinHodgkin's Lymphoma

Abbott67 participantsStarted Apr 2003

Phoenix, Arizona, United States • Tucson, Arizona, United States • Los Angeles, California, United States +11 more locations

COMPLETEDPhase 342 miles

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

NCT00039910

Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has been demonstrated to increase platelet counts. This study will test the safety and efficacy of the investigational drug in the prevention of thrombocytopenia in patients with recurrent or refractory intermediate-grade or high-grade non-Burkitt's, non-Hodgkin's lymphoma (NHL), or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine, and Cisplatin) chemotherapy.

Non-Hodgkin LymphomaHodgkin DiseaseThrombocytopenia

Pfizer240 participantsStarted Jul 2000

Phoenix, Arizona, United States • La Jolla, California, United States • Loma Linda, California, United States +35 more locations

PreviousPage 27 of 28Next

Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Lymphoma Trials in Other Cities

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Other Conditions in Arizona